Legal Status Overview
RestrictedPeptides are restricted in Louisiana rather than freely legal or flatly illegal: since Act 374 (2026 SB 253) took effect on August 1, 2026, state law (R.S. 37:23.5) affirmatively protects licensed prescribers' and pharmacists' ability to provide peptides, but only when those peptides come from an FDA-registered 503B outsourcing facility or a compliant 503A compounding pharmacy using FDA-registered active pharmaceutical ingredients. The Louisiana Board of Pharmacy separately regulates and has warned compounders against making unapproved forms of GLP-1 drugs like semaglutide and tirzepatide. Louisiana has no statute creating a distinct 'research chemical' or 'research-use-only' legal category, so peptides marketed that way (e.g., unprescribed BPC-157 or TB-500) fall outside any lawful sale pathway and rely on federal FDA/DSHEA rules, which treat them as unapproved drugs.
Key Points
- Louisiana's 2026 Act 374 (originally SB 253), codified at R.S. 37:23.5 and effective August 1, 2026, bars professional and occupational licensing boards from prohibiting authorized prescribers from providing patients with peptides. [1]
- Under R.S. 37:23.5, peptides prescribed in Louisiana must be sourced from an FDA-registered 503B outsourcing facility or a 503A compounding pharmacy that purchases active pharmaceutical ingredients from an FDA-registered manufacturer. [4]
- Louisiana law requires the prescribing provider to verify that any peptide they prescribe is not on the FDA's list of prohibited compounds before it can lawfully be dispensed. [1]
- A person cannot legally buy or bring unprescribed 'research use only' peptides like BPC-157 or TB-500 into Louisiana for human use, because no Louisiana statute or Board of Pharmacy rule creates a research-chemical exemption, leaving such products reliant only on federal FDA rules that treat them as unapproved drugs. [8]
- The Louisiana Board of Pharmacy has told compounding pharmacies to stop using unapproved forms of semaglutide, though its executive director has stated this warning does not amount to an outright ban on compounding semaglutide. [5]
- Federal law independently limits Louisiana's 503A compounding pharmacies from making semaglutide or tirzepatide that is 'essentially a copy' of the approved brand product unless there is a documented, individualized medical necessity, since the FDA's 2025 shortage listing for these drugs ended. [6]
- A secondary industry legal summary reports that Louisiana's Attorney General issued a May 2025 statewide notice to weight-loss clinics and medspas stating that compounding of semaglutide and tirzepatide is no longer permitted, though this claim comes from a secondary source and was not independently verified against a primary AG document. [7]
- Telehealth prescribing of peptides such as sermorelin is permissible in Louisiana as long as the prescriber holds a valid Louisiana medical license, since sermorelin itself is not a federally scheduled controlled substance. [10]
Peptide-by-peptide status in Louisiana
| BPC-157 | BPC-157 has no FDA approval and no Louisiana-specific exemption, so in Louisiana it can only reach a consumer lawfully as part of a valid prescription compounded by a 503A/503B facility under R.S. 37:23.5, while 'research use only' retail sales for human use fall outside any recognized legal channel. [9] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are FDA-approved as brand drugs (e.g., Ozempic, Wegovy, Mounjaro, Zepbound) and can be lawfully prescribed in Louisiana, but the Louisiana Board of Pharmacy has directed compounders to stop making unapproved forms and federal law now restricts 503A pharmacies from compounding copies of these drugs absent an individualized medical need. [5] |
| TB-500 | TB-500 is not FDA-approved and, like BPC-157, has no Louisiana-specific statute naming it, so it is only lawful in the state if provided through a valid provider prescription filled by a compliant 503A/503B compounding facility under R.S. 37:23.5; unprescribed 'research chemical' sales remain unregulated by a specific state rule and reliant on general federal drug law. [8] |
| Human Growth Hormone (HGH/somatropin) and GH-secretagogue peptides (e.g., sermorelin, CJC-1295) | Sermorelin and related growth-hormone secretagogue peptides are not scheduled under the federal Controlled Substances Act and can be legally prescribed and dispensed via telehealth in Louisiana by a provider holding a valid Louisiana license, whereas somatropin (recombinant HGH) itself is an FDA-approved prescription drug subject to standard prescribing rules rather than any Louisiana peptide-specific carve-out. [10] |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides like BPC-157 in Louisiana without a prescription?
No — in Louisiana, peptides such as BPC-157 have no lawful over-the-counter sales channel; state law (R.S. 37:23.5) only protects peptide access when a licensed prescriber orders them through a compliant 503A or 503B compounding facility, so unprescribed 'research use only' peptide sales for human use are not a recognized legal pathway. [1]
Is it legal to bring or ship peptides into Louisiana for personal use?
There is no Louisiana-specific personal-importation allowance for peptides; the only sourced legal pathway in the state is a prescription filled by an FDA-registered 503A or 503B facility under R.S. 37:23.5, so bringing in unprescribed peptides falls back on general federal FDA rules that treat unapproved peptide drugs as illegal to import for human use.
Can a telehealth doctor legally prescribe peptides in Louisiana?
Yes — telehealth prescribing of peptides such as sermorelin is permissible in Louisiana as long as the prescribing provider holds a valid Louisiana license, and under Act 374 (R.S. 37:23.5) the peptide must still be dispensed via a compliant 503A or 503B compounding facility. [10]
What happens if a pharmacy in Louisiana compounds semaglutide or tirzepatide improperly?
The Louisiana Board of Pharmacy can pursue regulatory and legal consequences against compounding pharmacies that use unapproved forms of semaglutide, since the Board has already warned compounders to stop, and federal law separately bars 503A pharmacies from compounding copies of these drugs without an individualized medical justification. [5]
Does Louisiana have a special 'research chemical' category that makes peptides legal outside a prescription?
No — no Louisiana statute, administrative rule, or Board of Pharmacy bulletin creates a distinct 'research chemical' or 'research-use-only' category for peptides, so any such labeling carries no special legal protection in the state and unprescribed peptides remain governed only by general federal FDA drug law. [8]